TCM
ADMS

Tekla Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Tekla Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,699
Closed -$399K – 194
2018
Q1 		$399K Buy
+16,699
New +$526K 0.02% 178
2017
Q1 		– Sell
-125,504
Closed -$2.12M – 146
2016
Q4 		$2.12M Buy
+125,504
New +$1.94M 0.09% 104

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Tekla Capital Management's ADMS Position: Q2 2018 in Review

Tekla Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2018, closing a stake of 16,699 shares — an estimated $399K sold.

Tekla Capital Management first reported a position in ADMS in Q4 2016 and held it in 2 quarters. The position peaked at $2.12M in Q4 2016. 126 funds tracked by Wall St. Rank hold ADMS as of Q2 2018.

  • Tekla Capital Management reported no remaining Adamas Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Tekla Capital Management sold 16,699 Adamas Pharmaceuticals shares in Q2 2018, an estimated $399K.
  • Tekla Capital Management first reported a position in Adamas Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Tekla Capital Management's Adamas Pharmaceuticals position peaked at $2.12M in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2018.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.